Back to Journals » OncoTargets and Therapy » Volume 9

PBOV1 promotes prostate cancer proliferation by promoting G1/S transition

Authors Pan T, Wu R, Liu B, Wen H, Tu Z, Guo J, Yang J, Shen G

Received 19 July 2015

Accepted for publication 11 November 2015

Published 16 February 2016 Volume 2016:9 Pages 787—795

DOI https://doi.org/10.2147/OTT.S92682

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ram Prasad

Peer reviewer comments 4

Editor who approved publication: Dr Jianmin Xu


Tiejun Pan,1,* Rongpei Wu,2,* Bo Liu,1 Handong Wen,1 Zhong Tu,1 Jun Guo,1 Jiarong Yang,1 Guoqiu Shen1

1Department of Urology, Wuhan General Hospital of Guangzhou Military Command, Wuhan, Hubei, 2Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Abstract: Prostate cancer (PC) is one of the leading causes of cancer death in men, and thus, finding new regulators is critical for PC therapy. Prostate and breast cancer overexpressed 1 (PBOV1) is overexpressed in breast, prostate, and bladder cancers, as it is upregulated in the serum of patients with PC, but the role of PBOV1 in PC has not been studied. In this article, we found that PBOV1 was indeed overexpressed in PC cells; PBOV1 overexpression promoted cell proliferation and colony formation ability and arrested cell cycle in the G0/G1 phase and tumorigenicity ability in vitro, whereas knockdown of PBOV1 reduced these effects. Further analysis of PBOV1 overexpression inhibited cell cycle inhibitors, P21 and P27, and increased the phosphorylation level of Rb and cyclin D1 expression, suggesting that PBOV1 promoted cell proliferation through promoting G1/S transition.

Keywords: prostate cancer, PBOV1, cell proliferation, G1/S transition

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]